三一重能(688349.SH):2023年員工持股計劃完成股票購買 累計買入235.25萬股
格隆匯9月11日丨三一重能(688349.SH)公佈,現將公司2023年員工持股計劃(以下簡稱“本期員工持股計劃”)如下:截至本公吿日,本期員工持股計劃已通過集中競價交易方式完成股票購買,累計買入本公司股票235.25萬股,佔公司總股本的0.20%,成交均價約30.84元/股。
根據《三一重能股份有限公司2023年員工持股計劃(草案)》,本期員工持股計劃的存續期為72個月,自公司公吿員工持股計劃專用賬户完成三一重能股票購買之日起計算。本期員工持股計劃所獲標的股票的鎖定期為12個月,自公司公吿完成三一重能股票購買之日起計算,在前述鎖定期內不得進行交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.